skip to Main Content

Marapharm Ventures Inc. Arranges $400,000 Private Placement

Vancouver, BC. – Les Kjosness, President & CEO of Marapharm Ventures Inc. (the ’Company’), is pleased to announce a non-brokered private placement is being arranged for Cdn. $400,000. The offering consists of 1,000,000 equity units at a price of $0.40 per unit. Each unit consists of one common share and one transferable share purchase warrant. Each full warrant entitles the holder to purchase one additional common share at an exercise price of $0.45 per share for a period of six months. This press release does not constitute an offer to sell, nor does it solicit an offer to buy in any jurisdiction. Proceeds from the private placement will be used for corporate activities. Additionally, the Company is granting 200,000 options with a two year expiry date, based at a price of $0.50 per share, to Linda Sampson whose key role is in marketing as part of the Management team.

 

About Marapharm Ventures Inc.
www.marpharm.com  

Marapharm was formed to create a global entity by pursuing commercial ventures in the medical marijuana business. The Company’s original project is the construction of brand new facilities on 11 acres in British Columbia’s Okanagan Valley with expansion plans in place to meet strategic advantages for growth and market penetration. Marapharm is currently in the process of its application for an MMPR license. In May 2015, we announced the purchase of 5.9 acres in the Apex Industrial Park, located in North Las Vegas, Nevada. The Company has a provisional grow licence in place and will build up to a 70,000 square foot medical marijuana facility. Completed building plans were revised and re-submitted for permitting. In addition to the Las Vegas acquisition, Marapharm has entered into an LOI with the same business corporation for a 90-day exclusive negotiation rights and the right of first refusal for two additional Nevada Medical Marijuana licences, one grow operation and a medical dispensary licence in Washington State and one medical dispensary licence in California.

On behalf of the Board
“Les Kjosness”
President & Director

For further information please visit the Company`s website at www.marapharm.com

The CSE has neither approved nor disapproved the accuracy of this news release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities – that could cause actual results to differ materially from the

Company’s expectations are disclosed in the Companies’ documents filed from time to time on SEDAR (www.sedar.com). Readers are cautioned not to place undue reliance on these forward – looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward – looking statements, whether as a result of new information, future events or otherwise.

Back To Top